AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
NUTX

Nutex Health Inc. Common Stock (NUTX) fair value

Healthcare · Medical Care Facilities · NASDAQ · United States
$209.59+1.70%
Market cap $1.4BNext earnings 2026-11-05Updated Oct 23, 2026
Add earnings to calendarGoogle
Our verdict
Trades 66% below our fair value
Price
$209.59
Model fair valueConfidence: good
$619
Model range
$426 to $705
Fair value $619
Price $210
3 models fit Nutex Health Inc. Common Stock and they disagree: 1 of 3 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Large discount(i)Silver75
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionNutex Health Inc. Common Stock (NUTX)
Fair value (3 models)
$619
ACCE price target
$225
Rating
Undervalued
Horizon
12 months
Fair value published on 23 Oct 2026, 10:03 CEST; previously $597 since 21 Oct 2026, 11:06 CEST.
ACCE price target published on 12 Oct 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 11:06 CEST.
Price used: $210 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
66.2% below
+195.5% to fair value
ACCE score
75
out of 100
Analysts
100% buy
5 covering
P/E
8.3x
forward 10.3x
1-year return
+78.7%
Dividend yield
0.00%

Nutex Health Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Nutex Health runs a network of outpatient hospitals and micro-hospitals across Texas and several other states, with the bulk of revenue coming from acute and elective procedures billed to commercial payers and Medicare Advantage plans. Its edge is a dense local footprint in its core Texas markets, which gives it referral density and pricing leverage that a national operator would struggle to replicate. The near-term story is a shift in mix toward higher-margin ambulatory and surgical volume, and the 57.8% operating margin against a 54.5% gross margin shows how much the recent cost structure is working in its favour. Revenue fell 13.6%, though, so the margins are being earned on a shrinking top line, and the question for a PM is whether that decline reflects deliberate pruning of unprofitable sites or a real loss of volume. The 8.0x trailing P/E and 64.6% ROE make the name cheap on earnings and the balance sheet deserves a look, but the absence of index membership and the zero forward P/E (no consensus estimate) mean this needs a deeper look at the revenue trajectory before anything else.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
  • high
    Revenue declining while earnings jump
    Revenue fell 13.6% year over year and 2.6% quarter over quarter, yet earnings rose 95.9%. Margin gains from a shrinking top line are harder to sustain.
  • high
    Heavy short interest
    Short interest stands at 28.9% of ownership. That level signals strong bearish conviction and can amplify volatility in either direction.
  • moderate
    Leverage and enterprise value stretch
    Debt to equity is 1.07 and EV/EBITDA is 90.0. The stock trades 6.8% below the ACCE price target of $225.00 and 66.2% below the model fair value of $619.42, so the gap reflects skepticism, not just cheapness.
  • moderate
    Score fell 10 points in 90 days
    The ACCE score dropped from 81 to 71 over 90 days, with growth at 43 and value at 56. The deterioration is concentrated in the growth and valuation pillars.

AI research notes

AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Free cash flow over the last 12 months reached $246M, and the stock's free cash flow yield stands at 18.8%.
  • Net margin of 21.3% and return on equity of 64.6% show the business turns sales into profit very efficiently.
  • Latest quarterly earnings per share beat expectations by 82.1%, and all five covering analysts rate the stock Buy or Strong Buy.
Why it could disappoint
  • Revenue fell 13.6% year over year, sharply reversing a five-year average growth rate of 26.1% per year.
  • Return on invested capital is only 8.5%, and debt equals 1.07 times equity, so returns depend heavily on borrowing.
  • The diluted share count rose 32.5% last fiscal year, so each share now represents a smaller slice of the business.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where NUTX's valuation models land
Price
$209.59
Model fair value
$619
Model range
$426 to $705
Fair value $619
Price $210
The price is below the whole model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish100% buy · 5 covering analysts
● Strong buy 4● Buy 1● Hold 0● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
0 buys · 1 sell
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+12.6%
1 month
+3.8%
3 months
+43.7%
6 months
+93.6%
YTD
+27.3%
1 year
+78.7%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
23 Oct 2026, 10:03 CESTFair value$619$597$206
21 Oct 2026, 11:06 CESTFair value$597$585$199
21 Oct 2026, 11:06 CESTRatingUndervaluedfirst publication$199
18 Oct 2026, 00:00 CESTFair value$585$596$186
17 Oct 2026, 00:00 CESTFair value$596$351$201
12 Oct 2026, 00:00 CESTACCE price target$225first publication$206
8 Oct 2026, 00:00 CESTFair value$351$457$218
5 Oct 2026, 00:00 CESTFair value$457$357$217
1 Oct 2026, 00:00 CESTFair value$357$464$210
28 Sept 2026, 00:00 CESTFair value$464$361$220

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full NUTX page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth43Value73Quality87Momentum97Total75
Valuation
Trailing P/E
8.3x
Forward P/E
10.3x
PEG
0.08
P/B
3.50x
EV / Revenue
1.2x
Book value/sh
$57.62
Enterprise value
$1.0B
Profitability
ROE
64.6%
FCF yield
18.15%
ROIC
8.5%
Health and risk
Debt / equity
1.07
Dividend yield
0.00%
Beta
2.00

Price

+66.9% · 1Y

Ask anything about NUTX

Answered from Nutex Health Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 8.3x8.3xhigh 44.7x
ROEbetter than 100% of peers
low 2%65%high 65%
Div yieldbetter than 50% of peers
low 0.0%0.0%high 4.5%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
NUTX Nutex Health Inc. Common Stock$209.59$61966% below8.3x64.6%8775
AMBEA.ST Ambea AB (publ)kr 183.40kr 21716% below19.1x15.5%4768
SIA.TO Sienna Senior Living Inc.C$20.55C$1186% above38.7x6.7%4250
ATT.ST Attendo AB (publ)kr 114.60kr 13515% below16.9x18.7%5263
AMN AMN Healthcare Services Inc$46.82$7134% below17.9x15.6%5273
ASTH Astrana Health Inc. Common Stock$38.01--44.7x6.9%3572
SGRY Surgery Partners Inc. Common Stock$15.90$1053% above-2.3%3343

Sector report card

Where NUTX ranks against its sector peers on each metric.

Computing percentiles…
  • PR Newswire•Sep 22, 2026
    Nutex Health Approved for Dual Listing on Nasdaq Texas
  • PR Newswire•Sep 10, 2026
    NUTEX HEALTH PROVIDES UPDATE REGARDING CYBERSECURITY EVENT
  • PR Newswire•Aug 31, 2026
    Nutex Health Hospitals Earn Multiple Community Honors in Second Quarter 2026
3 more press releases · full archive on Investor+.INVESTOR
40 filings
September 2026
Sep 18
Form 4Insider transactionPeriod 2026-09-18
View on SEC →
Sep 11
8-KCurrent reportPeriod 2026-09-10
View on SEC →
August 2026
Aug 31
8-KCurrent reportPeriod 2026-08-31
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR